Callida Genomics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.
Trademark Applications
Trademark applications show the products and services that Callida Genomics is developing and marketing.
Callida Genomics doesn't have any recent trademark applications, indicating Callida Genomics is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
PROBEUNIVERSE Bioanalytical devices containing nucleic acid and other reagents for analysis of nucleic acids and proteins, namely, microarrays, microparticles, nano-particles, and microfluidic chips; laboratory equipment, namely DNA sequencers, DNA analyzers, DNA preparation and extraction instruments, and DNA hybridization instruments, for use in handling reagents, preparing nucleic acid samples and screening nucleic acid samples, and laboratory equipment, namely, nucleic acid synthesizers, nucleic acid cross-linking equipment, nucleic acid amplification apparatus, and microarray/biochip scanners and detectors, for use in detecting the presence of analytes in samples, identifying molecular information about the samples, and automating the assay processes; equipment for making molecular arrays, biochips and bioanalytical devices, namely, microarray spotters, microarray printers, and liquid and sample handling and pipetting instruments; computer software for the collection, analysis and management of nucleic acid data, protein data, chemical data and biological data for use in the field of scientific research and commercial development
11/20/2002
CALLIDA Bioanalytical devices containing nucleic acid and other reagents for analysis of nucleic acids and proteins, namely, microarrays, microparticles, nano-particles, and microfluidic chips; laboratory equipment, namely DNA sequencers, DNA analyzers, DNA preparation and extraction instruments, and DNA hybridization instruments, for use in handling reagents, preparing nucleic acid samples and screening nucleic acid samples, and laboratory equipment, namely, nucleic acid synthesizers, nucleic acid cross-linking equipment, nucleic acid amplification apparatus, and microarray/biochip scanners and detectors, for use in detecting the presence of analytes in samples, identifying molecular information about the samples, and automating the assay processes; equipment for making molecular arrays, biochips and bioanalytical devices, namely, microarray spotters, microarray printers, and liquid and sample handling and pipetting instruments; computer software for the collection, analysis and management of nucleic acid data, protein data, chemical data and biological data for use in the field of scientific research and commercial development
11/14/2002
HYCHIP DNA testing apparatus, namely, a plastic or glass chip in the nature of a test slide which carries or hold DNA samples for use in screening and sequencing such samples for medical/diagnostic purposes
03/13/1997
See all trademarks and details in the Full Report.
Market Share of Callida Genomics's Largest Competitors
A competitive analysis shows these companies are in the same general field as Callida Genomics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Callida Genomics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Callida Genomics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.